Genetic Signatures Ltd Terminates Merger with Microba Life Sciences
Key points
- Genetic Signatures Ltd (GSS) has decided to not proceed with the Proposed Merger with Microba Life Sciences Limited (Microba)
- The decision follows Microba's announcement of insufficient financial capacity to complete the merger
- GSS will withdraw Resolution 4 from the upcoming annual general meeting
Full summary
Genetic Signatures Ltd (ASX: GSS) has decided to terminate its proposed merger with Microba Life Sciences Limited (ASX: MAP) due to Microba's announcement that it lacks the financial capacity to complete the merger without additional capital. After months of discussions and due diligence, GSS has resolved not to proceed with the merger. The company had been in talks with Microba regarding potential unsecured debt funding to support Microba's working capital needs during the merger process. However, the GSS Board ultimately decided against proceeding with such an arrangement due to associated risks and potential regulatory requirements. GSS will issue a separate announcement to formally withdraw Resolution 4 from the agenda of its upcoming annual general meeting on 30 November 2026.
Summary generated by a large language model. Please interpret with care.